62.49
1.35 (2.20%)
| Previous Close | 61.15 |
| Open | 60.37 |
| Volume | 222,885 |
| Avg. Volume (3M) | 821,746 |
| Market Cap | 3,727,832,064 |
| Price / Earnings (TTM) | 26.94 |
| Price / Earnings (Forward) | 15.55 |
| Price / Sales | 2.39 |
| Price / Book | 2.25 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2026 |
| Profit Margin | 8.81% |
| Operating Margin (TTM) | 11.83% |
| Diluted EPS (TTM) | 2.04 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Quarterly Earnings Growth (YOY) | 6.80% |
| Total Debt/Equity (MRQ) | 57.24% |
| Current Ratio (MRQ) | 4.87 |
| Operating Cash Flow (TTM) | 225.16 M |
| Levered Free Cash Flow (TTM) | 172.75 M |
| Return on Assets (TTM) | 4.32% |
| Return on Equity (TTM) | 9.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Merit Medical Systems, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | 0.0 |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.30 |
|
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 2.23% |
| % Held by Institutions | 109.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 109.00 (Barrington Research, 74.43%) | Buy |
| Median | 103.50 (65.63%) | |
| Low | 78.00 (Wells Fargo, 24.82%) | Hold |
| Average | 98.50 (57.63%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 79.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 26 Feb 2026 | 78.00 (24.82%) | Hold | 78.02 |
| Barrington Research | 25 Feb 2026 | 109.00 (74.43%) | Buy | 79.23 |
| Needham | 25 Feb 2026 | 101.00 (61.63%) | Buy | 79.23 |
| Piper Sandler | 18 Feb 2026 | 106.00 (69.63%) | Buy | 82.98 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ARONSON MARTHA GOLDBERG | 61.63 | - | 2,000 | 123,260 |
| LLOYD BRIAN G. | 62.33 | - | 2,000 | 124,660 |
| PARRA RAUL JR. | 61.63 | - | 1,500 | 92,445 |
| VOIGT MICHEL J. | 60.44 | - | 2,250 | 135,990 |
| WARD LYNNE N. | - | 62.33 | -5,000 | -311,650 |
| Aggregate Net Quantity | 2,750 | |||
| Aggregate Net Value ($) | 164,705 | |||
| Aggregate Avg. Buy ($) | 61.51 | |||
| Aggregate Avg. Sell ($) | 62.33 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LLOYD BRIAN G. | Officer | 07 May 2026 | Buy (+) | 2,000 | 62.33 | 124,660 |
| WARD LYNNE N. | Director | 07 May 2026 | Sell (-) | 5,000 | 62.33 | 311,650 |
| PARRA RAUL JR. | Officer | 06 May 2026 | Buy (+) | 1,500 | 61.63 | 92,445 |
| ARONSON MARTHA GOLDBERG | Officer | 06 May 2026 | Buy (+) | 2,000 | 61.63 | 123,260 |
| VOIGT MICHEL J. | Officer | 05 May 2026 | Buy (+) | 2,250 | 60.44 | 135,990 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |